Kamada (KMDA) Current Assets (2012 - 2026)
Kamada's (KMDA) quarterly Current Assets came in at $199.6 million in Q2 2026, up 8.9% on a YoY basis from $183.3 million in Q2 2025, and little changed quarter-over-quarter from $199.2 million in Q1 2026.
Analysis
Kamada (KMDA) Current Assets (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Current Assets for 13 consecutive years, with $199.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Current Assets rose 8.9% year-over-year to $199.6 million; the trailing twelve-month figure through Jun 2026 stood at $199.6 million (up 8.9% YoY), and the FY2025 full-year result was $193.1 million, up 4.73% from the prior year.
- Current Assets was little changed at $199.6 million in Q2 2026 per KMDA's latest filing, from $199.2 million in the prior quarter.
- Across five years, Current Assets topped out at $199.6 million in Q2 2026 and bottomed at $116.2 million in Q1 2022.
- Historically, Current Assets has averaged $162.4 million across 5 years, with a median of $165.4 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Current Assets plunged 33.87% in 2022, then gained 28.33% in 2024.
- Over 5 years, Current Assets stood at $139.0 million in 2022, then rose by 22.27% to $170.0 million in 2023, then advanced by 8.46% to $184.3 million in 2024, then rose by 4.73% to $193.1 million in 2025, then gained by 3.37% to $199.6 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $199.6 million, $199.2 million, and $193.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 34.96 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 13.95 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 12.54 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 18.45 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 8.07 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 5.82 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 7.31 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 4.74 Bn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | 199.57 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 199.57 Mn |
| Mar 31, 2026 | 199.24 Mn |
| Dec 31, 2025 | 193.08 Mn |
| Sep 30, 2025 | 192.73 Mn |
| Jun 30, 2025 | 183.27 Mn |
| Mar 31, 2025 | 188.50 Mn |
| Dec 31, 2024 | 184.35 Mn |
| Sep 30, 2024 | 164.41 Mn |
| Jun 30, 2024 | 166.43 Mn |
| Mar 31, 2024 | 157.81 Mn |
| Dec 31, 2023 | 169.96 Mn |
| Sep 30, 2023 | 153.15 Mn |
| Jun 30, 2023 | 129.68 Mn |
| Mar 31, 2023 | 131.40 Mn |
| Dec 31, 2022 | 139.01 Mn |
| Sep 30, 2022 | 135.16 Mn |
| Jun 30, 2022 | 118.60 Mn |
| Mar 31, 2022 | 116.16 Mn |
| Dec 31, 2021 | 130.04 Mn |
| Sep 30, 2021 | 178.94 Mn |